Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016834 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
A Phase 4 study, sponsored by Zogenix.
- Completed
- Registry status
- Phase 4
- Development phase
- 246
- Enrollment target
NCT01016834: Completed Phase 4 study, sponsored by Zogenix.
NCT01016834 is a Phase 4 study that has completed, run by Zogenix. The registered enrollment target is 246 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01016834, a Phase 4 study, has completed, sponsored by Zogenix.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
Primary Outcome
Overall participant satisfaction with migraine treatment Sumavel DosePro was measured using the Patient Perception of Migraine Questionnaire-Revised (PPMQ-R), question 3c "Overall satisfaction". The PPMQ-R scores (scale ranges from 1-7 with 1=very satisfied) were transformed to a 0-100 scale with higher scores indicating a higher level of treatment satisfaction (100=very satisfied).
Interventions
- DRUG Sumatriptan
- DEVICE Sumavel DosePro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2009-11-30 |
| Est. Completion | 2010-04-30 |
| Phase | Phase 4 |
What the finished NCT01016834 record still lists
NCT01016834 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Sumatriptan is the first listed.
NCT01016834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01016834 about?
NCT01016834 is a clinical study titled "Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine". The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
What is the current status of trial NCT01016834?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 246 participants. The study started on 2009-11-30. Estimated completion is 2010-04-30.
What interventions are being tested in trial NCT01016834?
The interventions under investigation include: Sumatriptan (DRUG), Sumavel DosePro (DEVICE).
Who is sponsoring clinical trial NCT01016834?
This trial is sponsored by Zogenix, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01016834's enrollment target sits among peer trials
246 356th of 2000 higher than 1,644 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI